Drug Interactions
Conditions
Keywords
HCV, SH229
Brief summary
The purpose of this study is to evaluate the drug-drug interaction of SH229 tablets and Daclatasvir dihydrochloride tablets. The study also evaluates the pharmacokinetics and tolerability of co-administration of SH229 tablets and Daclatasvir dihydrochloride tablets in healthy subjects. This study provides evidence for the designing of following clinical trial protocols.
Detailed description
A total of 28 evaluable healthy subjects will be enrolled in this study. The dose of SH229 is 600 mg. The dose of Daclatasvir dihydrochloride is 60 mg.
Interventions
DRUGSH229
tablet, oral, 600 mg once daily for day 1 to day 14
tablet, oral, 60 mg once daily for day 8 to day 14
Sponsors
Nanjing Sanhome Pharmaceutical, Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
MALE
Age
18 Years to 45 Years
Healthy volunteers
Yes
Inclusion criteria
1. Sign the informed consent form before the study and fully understand the study content, process and possible adverse reactions; 2. Be able to complete the study as required by the protocol; 3. Subjects (including their partners) who are willing to voluntarily take effective contraceptive measures from screening to 6 months after the last dose. See the appendix for specific contraceptive measures; 4. Male subjects aged 18-45 (including 18 and 45 years old); 5. Male subjects who weigh no less than 50 kg and have a body mass index between 18 and 28 kg / m2 (including the threshold). Body mass index (BMI) = weight (kg) / height2 (m2); 6. Physical examination and vital signs normal, or the abnormal signs have no clinical significance.
Exclusion criteria
1. Smoke more than 5 cigarettes per day within three months prior to study; 2. Subjects who are allergic to the study drugs or prone to allergies (Multiple drug and food allergies); 3. Subjects with history of drug and/or alcohol abuse (14 units per week: 1 unit = 285 mL of beer, or 25 mL of hard liquor, or 100 mL of wine); 4. Subjects with history of blood donation or massive blood loss (\> 450 mL) within three months prior to screening; 5. Subjects with dysphagia or have history of gastrointestinal disorders which affects study drug absorption; 6. Subjects with any diseases that increase the risk of bleeding, such as hemorrhoids, acute gastritis, or gastric and duodenal ulcers; 7. Use of any drugs that alter liver enzyme activity within 28 days prior to screening; 8. Use of any prescription drugs, over-the-counter drugs, vitamin products or herbal medicines within 14 days prior to screening; 9. Use of special diet (including dragon fruit, mango, grapefruit, etc.), strenuous activities or other factors that may affect the absorption, distribution, metabolism and excretion of the study drug within 2 weeks prior to screening; 10. Concomitant use of strong inhibitors or inducers of CYP3A4, P-gp or Bcrp, such as itraconazole, ketoconazole or dronedarone; 11. Subjects with major changes in diet or exercise habits recently; 12. Use of study drugs or participation in other clinical trials within three months prior to dosing; 13. Subjects who have ECG abnormalities with clinical significance; 14. Subjects who have abnormalities with clinical significant in clinical laboratory tests or other clinical findings that indicate clinically significant diseases (including but not limited to gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric or cardiovascular diseases); 15. Subjects with viral hepatitis (including hepatitis B and hepatitis C), AIDS antibody and/or antibody screening positive for Treponema pallidum; 16. Subjects with acute disease or concomitant use of drugs from screening stage to dosing; 17. Use of chocolate, food or beverages containing caffeine or xanthine within 24 hours prior to dosing; 18. Use of products containing alcohol within 24 hours prior to dosing; 19. Subjects with urine drug screening test positive, or with history of drug abuse in the past 5 years; 20. Subjects with any other reasons that investigator considers to be unsuitable for the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence of adverse events | Up to 1 month after last dose | Cohort A and Cohort B \[Safety and tolerability\] |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax, ss | Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose | Maximum observed concentration; safety and validity criteria |
| Cmin, ss | Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose | Minimum observed concentration; safety and validity criteria |
| t1/2, ss | Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose | Elimination half-life; safety and validity criteria |
| AUC0-24, ss | Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose | Area under the concentration-time curve (AUC) from time 0 to 24 hours; safety and validity criteria |
| Tmax, ss | Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose | Time of maximum observed concentration; safety and validity criteria |
| AUC0-∞, ss | Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose | Area under the concentration-time curve (AUC) from time 0 to infinity; safety and validity criteria |
| CL/F ss | Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose | Apparent clearance; safety and validity criteria |
| DF | Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose | Degree of fluctuation; safety and validity criteria |
| AUC0-72, ss | Day 5, 6, 7, 8, 12, 13, 14, 15, 16, 17 after first dose | Area under the concentration-time curve (AUC) from time 0 to 72 hours; safety and validity criteria |
Countries
China
Outcome results
None listed